CJC-1295 vs IGF-1 LR3: Literature and Handling Compared
Researchers comparing CJC-1295 and IGF-1 LR3 are usually resolving one question: which compound the published record actually supports for the model in front of them.
Compound profiles
CJC-1295 in the indexed record
Indexed output for CJC-1295 stands at 33 records, a limited literature, alongside 1 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Am J Sports Med, Growth Horm IGF Res, J Am Acad Orthop Surg Glob Res Rev, spanning 2006–2026.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — J Clin Endocrinol Metab, 2006. PMID: 16352683
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions — Subst Use Misuse, 2016. PMID: 26771670
IGF-1 LR3 in the indexed record
The literature on IGF-1 LR3 is a limited body of work: 11 PubMed-indexed records with no registered studies currently listed on ClinicalTrials.gov.
Publications carrying this compound include Am J Physiol Endocrinol Metab, Appl Microbiol Biotechnol, FASEB J, spanning 2020–2025.
- Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris — Appl Microbiol Biotechnol, 2023. PMID: 37261455
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep — Am J Physiol Endocrinol Metab, 2025. PMID: 39679943
- Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets — J Dev Orig Health Dis, 2023. PMID: 37114757
- Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration — Int J Biol Macromol, 2025. PMID: 41015370
How the literature differs
The indexed record is not symmetrical between these two compounds. CJC-1295 carries 22 more indexed records than IGF-1 LR3, which means published methodology, characterisation data and replication attempts are more readily located for CJC-1295. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (1 vs 0) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | CJC-1295 | IGF-1 LR3 |
|---|---|---|
| PubMed indexed records | 33 | 11 |
| Registered studies (ClinicalTrials.gov) | 1 | 0 |
| Literature depth | Emerging | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
CJC-1295 and IGF-1 LR3 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for CJC-1295 describes conditions validated for CJC-1295: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to IGF-1 LR3 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Selecting between them for a study design
CJC-1295 and IGF-1 LR3 are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (CJC-1295) generally offers more methodological precedent.
Documentation standards
Identity and purity are separate claims requiring separate methods. A purity percentage quoted without the analytical method behind it, or a certificate with no lot reference, is a documentation gap rather than verification.
Storage and stability
Lyophilised peptide is the stable form. Held sealed at -20°C and shielded from light, it tolerates long storage; once reconstituted that tolerance drops sharply and the working solution is treated as short-lived.
Each freeze-thaw cycle costs integrity, which is why reconstituted material is normally split into single-use aliquots.
Frequently asked questions
Which of CJC-1295 or IGF-1 LR3 has more published research?
CJC-1295, with 33 indexed PubMed records against 11.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are CJC-1295 and IGF-1 LR3 the same compound?
No. They are structurally distinct research compounds with separate literature records — 33 indexed records for CJC-1295 and 11 for IGF-1 LR3.
Related references
- CJC-1295 — product and lot documentation
- IGF-1 LR3 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.